JAK inhibitors abrogate the signaling of a wide range of proinflammatory cytokines in AD, including IL-4, IL-13, IL-22, IL-31, interferon gamma (IFN-γ), and thymic stromal lymphopoietin (TSLP). This evidence concerns the gene IFNG and Alzheimer disease.